Assessing T cell-mediated immune response to dystrophin in the natural history of Duchenne muscular dystrophy

Karen Anthony, Valeria Ricotti, Michela Guglieri, L Servais, Thomas Voit, Kate Bushby, Volker Straub, Jennifer Morgan, Francesco Muntoni

Research output: Contribution to journalAbstractResearchpeer-review

Abstract

The pre-symptomatic induction of inflammatory cascades and invasion of muscle by immune cells in dystrophin deficient muscle contributes to the pathology of Duchenne muscular dystrophy (DMD). Traditional and RNA-based gene therapy approaches for DMD are progressing through clinical development. Whilst in one study a post-treatment reduction in inflammatory infiltrate after antisense oligonucleotide-mediated exon skipping has been reported; another study, on viral delivered mini-dystrophin, has shown evidence that dystrophin epitopes expressed in revertant fibres can elicit T cell production in untreated patients which may accelerate a post-treatment immune response.

To extend this observation, we are performing annual ELISPOT IFN-gamma assays on patients recruited into a four year DMD natural history study. The study is recruiting 30 ambulant and 30 non-ambulant DMD boys with exon skippable deletions from three clinical centres. ELISPOT assays on all patients are performed with a full length dystrophin peptide set whilst patients with exon 51 or 53 skippable deletions are also assessed with peptides corresponding to unique epitopes generated by exon skipping. This allows us to assess pre-existing immunological responses to dystrophin epitopes in patients prior to inclusion in clinical trials, as well as the likelihood of a post-exon skipping immune response to newly-generated dystrophin protein.

Here we present the results to date from patients recruited during the first year; we correlated data to factors such as age, ambulation status, steroid regime and DMD deletion. The majority of patients did not have significant T cell activity against the full length or unique epitope peptide sets; whilst in those that did (approximately 1/6), the activity was relatively low. These ’positive’ patients are presented and the responses mapped to specific dystrophin peptides. Our data provides a useful immunological baseline for future DMD clinical trials.
Original languageEnglish
JournalNeuromuscular Disorders
Publication statusPublished - 2013

Fingerprint

Dystrophin
Duchenne Muscular Dystrophy
T-Lymphocytes
Exons
Epitopes
Enzyme-Linked Immunospot Assay
Peptides
Clinical Trials
Antisense Oligonucleotides
Natural History
Genetic Therapy
Muscle Cells
Walking
Steroids
RNA
Pathology
Muscles
Therapeutics

Cite this

Anthony, Karen ; Ricotti, Valeria ; Guglieri, Michela ; Servais, L ; Voit, Thomas ; Bushby, Kate ; Straub, Volker ; Morgan, Jennifer ; Muntoni, Francesco. / Assessing T cell-mediated immune response to dystrophin in the natural history of Duchenne muscular dystrophy. In: Neuromuscular Disorders. 2013.
@article{8a5f6fad26794ea39f925fa4316ed5c8,
title = "Assessing T cell-mediated immune response to dystrophin in the natural history of Duchenne muscular dystrophy",
abstract = "The pre-symptomatic induction of inflammatory cascades and invasion of muscle by immune cells in dystrophin deficient muscle contributes to the pathology of Duchenne muscular dystrophy (DMD). Traditional and RNA-based gene therapy approaches for DMD are progressing through clinical development. Whilst in one study a post-treatment reduction in inflammatory infiltrate after antisense oligonucleotide-mediated exon skipping has been reported; another study, on viral delivered mini-dystrophin, has shown evidence that dystrophin epitopes expressed in revertant fibres can elicit T cell production in untreated patients which may accelerate a post-treatment immune response.To extend this observation, we are performing annual ELISPOT IFN-gamma assays on patients recruited into a four year DMD natural history study. The study is recruiting 30 ambulant and 30 non-ambulant DMD boys with exon skippable deletions from three clinical centres. ELISPOT assays on all patients are performed with a full length dystrophin peptide set whilst patients with exon 51 or 53 skippable deletions are also assessed with peptides corresponding to unique epitopes generated by exon skipping. This allows us to assess pre-existing immunological responses to dystrophin epitopes in patients prior to inclusion in clinical trials, as well as the likelihood of a post-exon skipping immune response to newly-generated dystrophin protein.Here we present the results to date from patients recruited during the first year; we correlated data to factors such as age, ambulation status, steroid regime and DMD deletion. The majority of patients did not have significant T cell activity against the full length or unique epitope peptide sets; whilst in those that did (approximately 1/6), the activity was relatively low. These ’positive’ patients are presented and the responses mapped to specific dystrophin peptides. Our data provides a useful immunological baseline for future DMD clinical trials.",
author = "Karen Anthony and Valeria Ricotti and Michela Guglieri and L Servais and Thomas Voit and Kate Bushby and Volker Straub and Jennifer Morgan and Francesco Muntoni",
year = "2013",
language = "English",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier",

}

Anthony, K, Ricotti, V, Guglieri, M, Servais, L, Voit, T, Bushby, K, Straub, V, Morgan, J & Muntoni, F 2013, 'Assessing T cell-mediated immune response to dystrophin in the natural history of Duchenne muscular dystrophy', Neuromuscular Disorders.

Assessing T cell-mediated immune response to dystrophin in the natural history of Duchenne muscular dystrophy. / Anthony, Karen; Ricotti, Valeria; Guglieri, Michela; Servais, L; Voit, Thomas; Bushby, Kate; Straub, Volker; Morgan, Jennifer; Muntoni, Francesco.

In: Neuromuscular Disorders, 2013.

Research output: Contribution to journalAbstractResearchpeer-review

TY - JOUR

T1 - Assessing T cell-mediated immune response to dystrophin in the natural history of Duchenne muscular dystrophy

AU - Anthony, Karen

AU - Ricotti, Valeria

AU - Guglieri, Michela

AU - Servais, L

AU - Voit, Thomas

AU - Bushby, Kate

AU - Straub, Volker

AU - Morgan, Jennifer

AU - Muntoni, Francesco

PY - 2013

Y1 - 2013

N2 - The pre-symptomatic induction of inflammatory cascades and invasion of muscle by immune cells in dystrophin deficient muscle contributes to the pathology of Duchenne muscular dystrophy (DMD). Traditional and RNA-based gene therapy approaches for DMD are progressing through clinical development. Whilst in one study a post-treatment reduction in inflammatory infiltrate after antisense oligonucleotide-mediated exon skipping has been reported; another study, on viral delivered mini-dystrophin, has shown evidence that dystrophin epitopes expressed in revertant fibres can elicit T cell production in untreated patients which may accelerate a post-treatment immune response.To extend this observation, we are performing annual ELISPOT IFN-gamma assays on patients recruited into a four year DMD natural history study. The study is recruiting 30 ambulant and 30 non-ambulant DMD boys with exon skippable deletions from three clinical centres. ELISPOT assays on all patients are performed with a full length dystrophin peptide set whilst patients with exon 51 or 53 skippable deletions are also assessed with peptides corresponding to unique epitopes generated by exon skipping. This allows us to assess pre-existing immunological responses to dystrophin epitopes in patients prior to inclusion in clinical trials, as well as the likelihood of a post-exon skipping immune response to newly-generated dystrophin protein.Here we present the results to date from patients recruited during the first year; we correlated data to factors such as age, ambulation status, steroid regime and DMD deletion. The majority of patients did not have significant T cell activity against the full length or unique epitope peptide sets; whilst in those that did (approximately 1/6), the activity was relatively low. These ’positive’ patients are presented and the responses mapped to specific dystrophin peptides. Our data provides a useful immunological baseline for future DMD clinical trials.

AB - The pre-symptomatic induction of inflammatory cascades and invasion of muscle by immune cells in dystrophin deficient muscle contributes to the pathology of Duchenne muscular dystrophy (DMD). Traditional and RNA-based gene therapy approaches for DMD are progressing through clinical development. Whilst in one study a post-treatment reduction in inflammatory infiltrate after antisense oligonucleotide-mediated exon skipping has been reported; another study, on viral delivered mini-dystrophin, has shown evidence that dystrophin epitopes expressed in revertant fibres can elicit T cell production in untreated patients which may accelerate a post-treatment immune response.To extend this observation, we are performing annual ELISPOT IFN-gamma assays on patients recruited into a four year DMD natural history study. The study is recruiting 30 ambulant and 30 non-ambulant DMD boys with exon skippable deletions from three clinical centres. ELISPOT assays on all patients are performed with a full length dystrophin peptide set whilst patients with exon 51 or 53 skippable deletions are also assessed with peptides corresponding to unique epitopes generated by exon skipping. This allows us to assess pre-existing immunological responses to dystrophin epitopes in patients prior to inclusion in clinical trials, as well as the likelihood of a post-exon skipping immune response to newly-generated dystrophin protein.Here we present the results to date from patients recruited during the first year; we correlated data to factors such as age, ambulation status, steroid regime and DMD deletion. The majority of patients did not have significant T cell activity against the full length or unique epitope peptide sets; whilst in those that did (approximately 1/6), the activity was relatively low. These ’positive’ patients are presented and the responses mapped to specific dystrophin peptides. Our data provides a useful immunological baseline for future DMD clinical trials.

M3 - Abstract

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

ER -